id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-D-1137-0118,FDA,FDA-2020-D-1137,"Guidance Documents Related to
Coronavirus Disease 2019; Availability",Notice,Notice of Availability,2022-04-22T04:00:00Z,2022,4,2022-04-22T04:00:00Z,,2022-04-25T03:50:54Z,2022-08564,0,0,090000648502d74a
FDA-2020-D-1137-0114,FDA,FDA-2020-D-1137,Emergency Use Authorization for Vaccines to Prevent COVID-19; Guidance for Industry,Other,Guidance,2022-03-31T04:00:00Z,2022,3,2022-03-31T04:00:00Z,,2022-04-25T03:47:04Z,,0,0,0900006484ff005c
FDA-2020-D-1137-0111,FDA,FDA-2020-D-1137,Guidance Documents Related to Coronavirus Disease 2019; Availability,Notice,Notice of Availability,2022-01-21T05:00:00Z,2022,1,2022-01-21T05:00:00Z,,2022-04-25T03:47:44Z,2022-01146,0,0,0900006484f2cfeb
FDA-2020-D-1137-0112,FDA,FDA-2020-D-1137,Policy for Certain REMS Requirements During the Tocilizumab Shortage Related to the COVID-19 Public Health Emergency; Guidance for Industry and Health Care Professionals,Other,Guidance,2022-01-21T05:00:00Z,2022,1,2022-01-21T05:00:00Z,,2024-11-07T00:36:13Z,,1,0,0900006484f2d2c6